When AI Designs a Drug, Who Gets the Patent Credit?
US courts have ruled that AI cannot be legally recognized as an inventor.
1AI's Role in Drug Discovery
Insilico Medicine announced a pulmonary fibrosis drug candidate as 'discovered entirely by AI,' yet the patent application credited five human inventors. This discrepancy highlights how current laws disregard AI's pivotal role in discovery. US courts have consistently ruled that AI systems, despite their creative output, cannot be legally recognized as inventors under statutes defining inventors as 'individuals'—meaning humans only.
2The DABUS Case Legal Precedent
Attorney Ryan Abbott filed a patent naming DABUS AI as the inventor of an optimized food container. In 2022, a DC appeals court emphasized that US law defines inventors strictly as human 'individuals.' This landmark decision clarified that AI's creative capacity doesn't translate to legal inventorship status, setting a binding precedent for future cases involving AI-generated innovations.
3Patent Office's Contradictory Stance
The US Patent Office treats AI as a mere tool—comparable to a calculator—not requiring disclosure in applications. While the Biden administration issued guidelines to assess human contribution, these were later revoked. This policy vacuum creates uncertainty about patentability of AI-assisted discoveries. Legal experts unanimously agree that IP laws must evolve to address AI's expanding role in invention processes.
4Legal Necessity of Human Involvement
Sarah Korman, Isomorphic Labs' legal chief, states, 'No human inventor means no patent.' At Insilico, human chemists handle synthesis, variant creation, and animal testing—steps legally required for patent eligibility. CEO Zhavoronkov notes, 'Even with full automation, someone still approves the budget,' underscoring how current systems mandate human touchpoints for legal compliance.
5Future Legal Battles on the Horizon
Abbott warns that AI-generated drug patents risk invalidation if challenged for incorrect inventorship. The US Copyright Office's refusal to recognize AI-generated content has alarmed industries like filmmaking. Experts argue that the Constitution's 1787 innovation clause—designed to 'promote Science and useful Arts'—requires modernization to accommodate AI's disruptive potential in medical research and beyond.
6The Creativity Paradox of AI
While the patent office acknowledges that 'AI can perform acts equivalent to human inventorship,' it denies legal consequences. Ambiguity persists—if an AI like Claude cured cancer, would the prompt-giver qualify as inventor? Abbott contends that denying protection for AI outputs could stifle pharmaceutical innovation, creating disincentives for cutting-edge research methodologies.
7Industry's Transition Strategy
Leading AI drug firms mitigate risk by maintaining human involvement and meticulous documentation. Companies like Insilico blend AI's design speed with human expertise. However, as AI's autonomous discovery capabilities grow, the sustainability of current patent systems faces scrutiny. The industry adheres to 'human touch' protocols as a temporary safeguard until regulatory frameworks catch up with technological realities.
8The Future of Innovation Law
AI's encroachment into creative domains is fundamentally challenging IP concepts. The US Constitution's innovation clause awaits reinterpretation for the AI age. Experts warn that human-centric patent systems may inadvertently delay medical breakthroughs by constraining AI's potential. This legal uncertainty underscores the urgent need for global regulatory collaboration to redefine inventorship in an era of machine-generated discoveries.
Original article: MIT Technology Review — Yapay Zeka İlaç Tasarladığında Kredi Kimin Olacak?